Infant Bacterial Therapeutics AB (CHIX:IBTBS) Minority Interest: kr0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CHIX:IBTBS Infant Bacterial Therapeutics AB CHIX:IBTBS
25 GF Score
Price kr109.00
! 1 Warning Sign
View Full Analysis

What is Infant Bacterial Therapeutics AB Minority Interest?

Infant Bacterial Therapeutics AB CHIX:IBTBS 25 Minority Interest is kr0.00 Mil as of Mar. 2026. GuruFocus rates CHIX:IBTBS with a GF Score™ of 25/100. The stock has 1 warning sign investors should review.

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Infant Bacterial Therapeutics AB's minority interest for the quarter that ended in Mar. 2026 was kr0.00 Mil.

Infant Bacterial Therapeutics AB Minority Interest Historical Data

* Premium members only.

The historical data trend for Infant Bacterial Therapeutics AB's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Infant Bacterial Therapeutics AB Minority Interest Chart

Infant Bacterial Therapeutics AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Minority Interest
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Infant Bacterial Therapeutics AB Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Minority Interest Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
CHIX:IBTBS
25GF Score
Infant Bacterial Therapeutics AB CHIX:IBTBS
Minority Interest is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Infant Bacterial Therapeutics AB Minority Interest Calculation

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Frequently Asked Questions Learn more about Minority Interest →
What does a Minority Interest of kr0.00 Mil mean?
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a Minority Interest of kr0.00 Mil as of Mar. 2026. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Infant Bacterial Therapeutics AB.
Is Infant Bacterial Therapeutics AB's Minority Interest too high?
Infant Bacterial Therapeutics AB's current Minority Interest is kr0.00 Mil. Overall, Infant Bacterial Therapeutics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Infant Bacterial Therapeutics AB's Minority Interest compare to VRTX and REGN?
Infant Bacterial Therapeutics AB's Minority Interest of kr0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Minority Interest for a Biotechnology company?
A good Minority Interest depends on the Biotechnology industry context. However, Minority Interest should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Minority Interest mean?
A high Minority Interest can signal that a stock is expensive relative to its fundamentals. Minority interest represents the carrying value of equity from non-controlling shareholders and company partners. View historical data on Infant Bacterial Therapeutics AB. Infant Bacterial Therapeutics AB's current Minority Interest is kr0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Infant Bacterial Therapeutics AB stock overvalued right now?
Infant Bacterial Therapeutics AB (CHIX:IBTBS) has a current Minority Interest of kr0.00 Mil. The current Minority Interest is kr0.00 Mil. Infant Bacterial Therapeutics AB's overall GF Score™ is 25/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Minority Interest calculated?
Minority Interest is calculated from a company's financial statements. For Infant Bacterial Therapeutics AB (CHIX:IBTBS), the current Minority Interest is kr0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Infant Bacterial Therapeutics AB Business Description

Other Exchanges IBT B:Sweden9IB:Germany
Address Katarina Bangata 70, Stockholm, SWE, 116 42
Infant Bacterial Therapeutics AB is a pharmaceutical company. Its purpose is to develop and commercialize drugs for diseases affecting premature babies. Its focus is on the drug candidate IBP-9414, whose development program is designed to show a reduced incidence of necrotizing enterocolitis (NEC) and improved gastrointestinal function (SFT) when treated with IBP-9414's active substance, Lactobacillus reuteri bacterial strain naturally found in human breast milk. Its portfolio also includes additional drug candidates, IBP-1016, IBP-1118, and IBP-1122. IBP1016, for the treatment of gastroschisis, is a life-threatening and rare disorder in which children are born with externalized gastrointestinal organs.
25GF Score

Get the complete analysis for CHIX:IBTBS

Minority Interest is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr109.00
Price